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Objective: To identify lipodystrophy in prepubertal HIV-infected children using anthropo-
metric  parameters and body composition assessment.
Methods: Cross-sectional study including 40 prepubertal HIV-infected children of both gen-
ders  seen at the Care Center of the Division of Pediatric Infectious Diseases – Universidade
Federal  de São Paulo, São Paulo city, Brazil, was carried out from August to December
2008.  Age, clinical and immunological status, prophylaxis, transmission and highly active
antiretroviral  therapy were recorded. Body mass index z-score and height-for-age z-score
were  calculated to characterize the nutritional status. Circumferences were measured with
ﬂexible  tape and skinfolds were assessed by an adipometry. Fat mass and lean mass were
determined  by dual-energy X-ray absorptiometry. Presence of clinical signs of lipodystrophy
was  assessed by a trained clinician. Data were analyzed using SPSS 12.0 software.
Results: The mean age and standard deviation were 9.8 (1.2) years, 50% were  girls and 82.5%
children  from B and C categories. Clinical lipodystrophy and dislypidemia were present in
27.5% and 70%, respectively. The trunk to arm ratio and the limb to trunk ratio had posi-
tive  association with lipodystrophy. Patients with lipodystrophy had short stature, higher
triglycerides  values and lower HDL-cholesterol.
Conclusion: The ratios obtained by skinfolds and dual-energy X-ray absorptiometry measure-ments  can be considered as indicators of preclinical lipodystrophy. The cutoff points have
not  been determined yet; however, continuous assessment may be useful to identify early
body  composition changes.
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iﬁcantly  reduced morbidity and mortality in HIV-infected
hildren. A U.S. multicenter study showed that, between 1994
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Este é um artigo Open Access sob a licença and 2000, the death rate decreased from 7.2 to 0.8 per 100 chil-
dren/year,  remaining stable until 2006.1 In Brazil, probability of
survival  to 60 months has increased from 52.8% among chil-ua Loefgreen, 1647, 04040-032, São Paulo, SP, Brazil.
dren  diagnosed during the period between 1983 and 1998 to
86.3%  among children born from 1999 to 2007.2 Assuredly, in
addition  to preserve or restore the immune system, the use
de CC BY-NC-ND
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of HAART also contributes to maintain or improve weight for
height  growth.3
Nonetheless, HIV infection itself and the use of antiretro-
viral  therapy cause clinical and metabolic changes initially
described in adults in the late 90s4 and subsequently observed
in  children and adolescents.5 Due to precocity and large expo-
sure  to the drug, especially in infections acquired by vertical
transmission, this population shows higher risks of develop-
ing  adverse effects of antiretroviral therapy.5
Among other metabolic side effects of antiretroviral
therapy, we  mention the lipodystrophy syndrome, which
comprises lipodystrophy, dyslipidemia, insulin resistance and
cardiovascular  risk.6 Lipodystrophy is identiﬁed and charac-
terized  by the use of clinical parameters, which causes several
difﬁculties.7,8 Anthropometric measurements and assess-
ment  of body composition are useful instruments to monitor
the  evolution of growth, also being useful to identify the pres-
ence  of clinical and metabolic changes.9 Therefore, this study
aims  to identify lipodystrophy in prepubertal HIV-infected
children through anthropometric measurements and body
composition  assessments.
Methods
We  carried out a cross sectional study with 52 prepubertal chil-
dren  (7–12 years old), both genders, seen at the Care Center
of  the Division of Pediatric Infectious Diseases (CEADIPe) of
the  Department of Pediatrics of UNIFESP/EPM from August to
November 2008. Children with genetic syndrome or neurop-
athy  were  not included. One hospitalized patient died, ﬁve had
neuropathy  and six were  not allowed by the caregiver to partic-
ipate  in the study. Thus, the ﬁnal sample totaled 40 patients.
The  study was  approved by the Research Ethics Committee
of  the Universidade Federal de São Paulo and initiated upon
consent  in writing of parents or guardians.
Pubertal stage was  assessed by the pediatrician, who used,
as  a criterion, the development of the secondary sexual char-
acteristics  proposed by Marshall and Tanner,10 including the
study  children and adolescents who showed staging.1 In order
to  classify the disease, we  used the clinical parameters and
immunological categories proposed by the Ministry of Health,3
which adopted the guidelines from the Centers for Disease
Control  and Prevention (CDC),11 in addition to inclusion of
pulmonary  tuberculosis as a criterion in clinical category B.
Data on identiﬁcation, age, type of transmission, pro-
phylaxis, patient’s legal caregiver and/or guardian and
antiretroviral regimen were collected from the medical records
of  these patients. Clinical lipodystrophy was  clinically iden-
tiﬁed  by the pediatrician, showing three characterizations:
lipoatrophy, lipohypertrophy and mixed lipodystrophy.12
Weight and height measurements were used to calculate
the  body mass index z-score (zBMI) and height-for-age z-score
(HAz),  pursuant to the reference standard and recommen-
dation of the World Health Organization.13 Skinfolds were
measured by using an adipometer under the brand Lange®(Beta Technology Inc., Santa Cruz, CA, USA) with precision
of  1 mm,  and circumferences were  measured with a ﬂexi-
ble,  non-extendable tape graduated in 0.1-cm. Trunk to arm
ratio  was  calculated through the sum of the subscapular and 2 0 1 3;1 7(1):1–6
suprailiac  skinfold divided by the value resulting from the
sum  of biceps and triceps skinfolds.12 Body composition was
assessed  through dual-energy X-ray absorptiometry (DXA)
by  only one trained technician (equipment LUNARTM DPX-L,
pediatric software, version 1.5). The ratio limb to trunk was
obtained  by adding the fat (g) in arms and legs and dividing it
by  the fat value (g) in trunk.
HIV  viral load was  determined through the RT-PCR tech-
nique  (Cobas Amplicor HIV-1 MonitorTM Test, version 1.5)
and  T CD4 and T CD8 lymphocytes were assessed through
ﬂow  cytometry (BD FACSCaliburTM System). The lipid pro-
ﬁle  was determined through reﬂectance spectrophotometry
– colorimetry – 540 nm (Vitros Systems Chemistry 750 XRC
–  Ortho-Clinical Diagnostics, Inc. – Johnson & Johnson Com-
pany,  New York, NY, USA), using the cutoffs proposed by
Kwiterovich.14 Blood glucose was measured through the enzy-
matic  method using hexokinase and glucose-6-phosphate
dehydrogenase enzyme (Advia Chemistry System 1650 –
Bayer)  and insulin through an immunoenzymatic method
(Tosoh–Tosoh Corporation, Tokyo, Japan). Fasting insulin and
blood  glucose were  used to calculate the homeostatic model
assessment-insulin resistance (HOMA-IR), which character-
izes  insulin resistance when HOMA-IR > 3.15 Skeletal muscle
mass  was  calculated pursuant to Heymsﬁeld et al.16
For statistical analysis, we used the Statistical Package
for  the Social Sciences (SPSS) program version 12.0. To com-
pare  qualitative variables, we  used the Chi-square test or
Fisher’s  Exact test. To compare quantitative variables, we  used
Student’s  t-distribution test. Shapiro–Wilk test was  used to
assess  the normality of continuous quantitative variables.
Those showing no regular distribution were transformed into
logarithm  (log10) for the statistical tests. We  computed the
Pearson’s  correlation coefﬁcient in order to show the degree
of  linear correlation between the variables. A linear regres-
sion  model was  prepared to investigate the determinants of
lipodystrophy.  The trunk to arm ratio was used as a depend-
ent  variable. A correlation matrix was developed, provided
that  the entry in the model followed the ascending order
with  value p < 0.20. The variables that adjusted the model and
remained  signiﬁcant were maintained in the ﬁnal model. Val-
ues  of p < 0.05 were deemed signiﬁcant.
Results
In this study, the ﬁnal sample comprised 40 prepubertal chil-
dren,  where 50% of the sample were female, with an average
age  and age standard deviation of 9.8 ± 1.2 years. HIV infec-
tion  occurred through vertical transmission in 39 (97.5%) of the
prepubertal  children, provided that 23 (56.4%) did not receive
any  type of prophylaxis during the gestational and perina-
tal  stage and the ﬁrst months of life. With respect to clinical
and  immunological classiﬁcation, 33 (82.5%) were  linked to
clinical  parameters B and C and 16 (40%) to immunological
classiﬁcation 3. Clinical lipodystrophy was  identiﬁed in 11
(27.5%,  IC 95%: 14.6–43.9) patients, three (7.5%) characterized
as  lipohypertrophy, four (10%) as lipoatrophy and four (10%)
as  mixed lipodystrophy. Antiretroviral therapy combined with
three  drugs was  used by 30 (75%) study patients and 21 of
them  (52.5%) used therapeutic regimen with protease inhibitor
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Table 1 – Characterization, nutritional status, antiretroviral drug, metabolic changes and immunological and biochemical
parameters of HIV-infected prepubertal children with and without lipodystrophy.
Variables With lipodystrophy (n = 11) Without lipodystrophy (n = 29) p
n (%) n  (%)
Malea 4 (36.4) 16 (55.2) 0.288
Vertical transmissiona 11 (100) 28 (96.6) 0.999
Clinical classiﬁcation B and Ca 10 (90.9) 23 (79.3) 0.650
Nutritional status
Eutrophya 10 (90.9) 23 (79.3) 0.650
Short staturea 4 (36.4) 2 (6.9) 0.020
Used medications
PIa 6 (54.5) 15 (51.7) 0.873
NRTIa 10 (90.9) 24 (82.8) 0.999
NNTRIa 3 (27.3) 7 (24.1) 0.295
Metabolic changes
Hypertriglyceridemiaa 6 (54.5) 10 (34.5) 0.295
Hypercholesterolemiaa 1 (9.1) 12 (41.4) 0.068
Increase in LDL-ca 1 (9.1) 6 (20.7) 0.650
Decrease in HDL-ca 5 (45.5) 22 (75.9) 0.128
Hyperglycemiaa 0 2 (6.9) 0.999
HOMA-IR > 3a 1 (9.1) 0 0.999
Average (SD) Average (SD)
Age  (years)b 10.2 (1.1) 9.6 (1.2) 0.179
Immunological parameters
Viral  load (log)b 3.2 (1.3) 2.8 (1.3) 0.310
CD4 (cells/mm3)b 939.1 (923.1) 740.8 (409.7) 0.349
CD8 (cells/mm3)b 1199.1 (313.4) 1059.2 (644.6) 0.497
Biochemical parameters
Triglycerides (mg/dL)b 160.6 (87.9) 112.7 (54.4) 0.044
Total cholesterol (mg/dL)b 142.9 (33.6) 158.4 (36.3) 0.227
LDL-cholesterol (mg/dL)b 76.6 (34.9) 88.3 (28) 0.273
HDL-cholesterol (mg/dL)b 34.6 (8.6) 45.9 (14.3) 0.019
Blood glucose (mg/dL)b 82.3 (6) 84.8 (9.4) 0.422
HOMA-IRb 1.2 (1.1) 0.7 (0.5) 0.150
HOMA-IR, homeostatic model assessment-insulin resistance; NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse
transcriptase inhibitors; PI, protease inhibitors. Bold values mean the values that presented statistical difference.
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wa Chi-square test or Fisher’s Exact test.
b Student’s t-test.
PI). Time of exposure to antiretroviral therapy in this popula-
ion  was  7.8 ± 2.4 years. As for the nutritional condition, 33
82.5%)  were  eutrophic, 6 (15%) overweight/obese and 34 (85%)
howed  proper height. The prevalence of dyslipidemia in the
tudy  population was  70% (28 children). Regarding metabolic
hanges, 16 patients (40%) showed hypertriglyceridemia, 13
32.5%)  hypercholesterolemia, 13 (32.5%) a decrease in HDL
holesterol  serum levels and 7 (17.5) an increase in LDL choles-
erol  serum levels. Insulin resistance was  found in 1 (2.5%)
atient.
In  Table 1, we  compared clinical variables and immuno-
ogical and laboratory parameters of patients in the presence
r  absence of lipodystrophy. The trunk to arm ratio, obtained
hrough  skinfolds, showed a strong association with the pres-
nce  of lipodystrophy, as well as the ratio limb to trunk
etermined through DXA (Table 2). When correlated, these
ariables  showed a moderate negative correlation (r = −0.69;
 = 0.000) (Fig. 1).
With respect to waist circumference and other variables,
e  noted a positive correlation with trunk to arm ratio(r  = 0.42; p < 0.007) and with zBMI (r = 0.68; p = 0.003) and a
negative  correlation with the limb to trunk ratio (r = −0.68;
p  = 0.000). The trunk to arm ratio also showed a positive corre-
lation  with insulin (r = 0.48; p = 0.001) and HOMA-IR (r = 0.45;
p  = 0.004), showing metabolic changes resulting from cen-
tral  adiposity. As for biochemical tests, T CD4 lymphocytes
and viral load showed a positive and negative correlation
with total cholesterol (r = 0.41; p < 0.008; r = −0.50; p = 0.001) and
LDL  cholesterol (r = 0.49; p = 0.001; r = −0.65; p = 0.000), respec-
tively.  Viral load also showed a negative correlation with HAz
(r  = −0.47; p = 0.002).
The linear regression used the trunk to arm ratio as a
control  variable and showed association with the arm circum-
ference  (  ˇ = 0.71; p = 0.045; IC 95%: 0.017–1.41) and HOMA-IR
(ˇ  = 0.14; p = 0.026; IC 95%: 0.018–0.271).Discussion
Prevalence of lipodystrophy in the study population (27.5%)
was  similar to results obtained in other groups, such as the
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Table 2 – Average and standard deviation of anthropometric measures/indexes and fat percentage (%) assessed through
DXA of prepubertal HIV-infected children with and without lipodystrophy.
Variables With lipodystrophy
(n = 11)
Average  (SD)
Without lipodystrophy
(n  = 29)
Average  (SD)
p
zBMI −0.2 (1.7) 0.0 (1.3) 0.764
HAz −1.1 (1.7) −0.7 (1.1) 0.532
Waist circumference (cm) 64.7 (8.8) 59.6 (6.5) 0.051
Arm circumference (cm) 19.1 (2.2) 18.6 (2.8) 0.601
Calf circumference (cm) 25.6 (2.1) 26.1 (3.2) 0.633
Triceps skinfold (mm) 7.4 (1.6) 8.8 (3.2) 0.079
Biceps skinfold (mm) 4.9 (2.3) 6.0 (2.1) 0.184
Subscapular skinfold (mm) 7.2 (3.5) 6.3 (1.9) 0.316
Suprailiac skinfold (mm) 7.7 (5.2) 6.1 (2.9) 0.240
Trunk to arm ratio 1.2 (0.4) 0.9 (0.2) 0.024
Skeletal muscle mass index 5.36 (0.6) 5.07 (0.7) 0.227
Lean body mass DXA (%) 79.9 (14.1) 83.1 (8.2) 0.491
Lean body mass DXA (kg) 25 (12.2) 24.2 (4.4) 0.850
Total fat DXA (%) 17.88 (8.4) 16.91 (8.2) 0.746
Total fat DXA (kg) 5.5 (4.12) 5.25 (3.6) 0.860
Arm fat DXA (%) 10.8 (9.6) 11.5 (7.7) 0.807
Leg fat DXA (%) 15.5 (6.8) 21.1 (9.6) 0.085
Trunk fat DXA (%) 20.1 (10.7) 18.1 (9.4) 0.564
Android fat DXA (%) 24.9 (13.7) 17.7 (9.6) 0.066
Gynoid fat DXA (%) 23.5 (8.8) 29.3 (9.2) 0.076
DXA-limb to trunk ratio 0.7 (0.2) 1 (0.2) 0.001
mpedzBMI, body mass index z-score; HAz, height-for-age z-score; BIA, bioi
values that presented statistical difference.
US population (29%).17 Another Brazilian assessment found
lipodystrophy in 14% of HIV-infected children.18
Scientiﬁc evidences suggest that lipohypertrophy and
lipodystrophy itself are more  frequent in pubescent children,
as  sexual maturity and hormonal factors may  contribute
to  this outcome.12,19 The diagnosis of lipohypertrophy and
mixed  lipodystrophy in prepubertal children in this study may
be  explained by the advanced classiﬁcation of the disease
and  high prevalence of dyslipidemia. Lipodystrophy, insulin
resistance  and dyslipidemia, with subsequent increase in car-
diovascular  risk, characterize the lipodystrophy syndrome,
in  which etiology seems to be related with some classes of
antiretroviral drugs, such as PI and nucleoside reverse trans-
criptase  inhibitors (NRTI); duration of drug administration;
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Fig. 1 – Pearson’s correlation between the ratio limb to
trunk  obtained through DXA and trunk to arm ratio
obtained through skinfolds (r = −0.69; p = 0.000). DXA,
dual-energy X-ray absorptiometry.ance; DXA, dual-energy X-ray absorptiometry. Bold values mean the
increase  in viral load; low levels of CD4 and prior increase in
serum  levels of triglycerides and cholesterol.4,6
In this study population, there is a higher serum level
of  triglycerides and lower HDL cholesterol in patients with
body  fat redistribution. The European cohort related the pres-
ence  of lipodystrophy with levels of triglycerides, insulin and
blood  glucose.20 A Spanish study with heterogeneous pedi-
atric  population (21 months to 18 years old) veriﬁed a higher
prevalence of lipodystrophy within the higher age group and in
the presence of hypertriglyceridemia, with no positive associ-
ation  with viral load, T CD4 lymphocyte, total cholesterol and
glucose.  With respect to classes of antiretroviral drugs, we  did
not  note association with lipodystrophy. The current literature
evidences  conﬂicting data as to the presence of lipodystrophy
associated with the use of PI. A US study with a population
averaging 11.9 years showed no association21 between the
drug  use and this clinical change, while another Brazilian
work, with a population averaging 9.1 years, veriﬁed a positive
association between these two variables.22
The use of antiretroviral therapy plays a positive role
as  to maintenance or improvement of nutritional condi-
tion,  however, in children with lipodystrophy, we  noted a
higher  prevalence of short stature. Hormonal factors, nutri-
tional  condition, gastrointestinal and endocrine disorders,
insufﬁcient food intake and recurrent infection may  also com-
promise  height development.23,24 The mechanism by which
this  impairment occurs is not very well described in the litera-
ture,  and it is possible to ﬁnd divergences between researchers
23,25and  reviews with respect to this topic.
HIV infection is also characterized by hormonal dis-
orders, of which we highlight the impairment of growth
hormone/insulin-like growth factor-1 (GH/IGF-1). There seems
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o be a resistance to GH, with increase in its levels and
ecrease in IGF-1.26 Another hypothesis would be a change in
GF-1  levels, resulting from the improper synthesis of insulin-
ike  growth factor binding protein-1 (IGFBP-1) and increase
n  insulin-like growth factor binding protein-3 (IGFBP-3).25
n infected children, resistance to GH and changes in pro-
uction  of cortisol directly affect the body mass and growth
nterruption.27 Interaction between hormonal disorders and
ipodystrophy seems to be related to an increase in somato-
tatin  tone, which will inhibit secretion of GH, decrease in
hrelin  and decrease of GH caused by the increase in free fatty
cids.28
GH and IGF-I act directly in muscle ﬁbers, increasing
rotein synthesis and body mass. Nonetheless, in chronic
iseases such as AIDS, the stress generated by a permanent
nﬂammatory condition contributes through hepatic gluco-
eogenesis  to the depletion of essential amino acids of the
keletal  muscle.23 The fast loss of muscle mass results from
cceleration in protein breakdown and degradation of myoﬁb-
illar  proteins through activation of the ubiquitin proteasome
ystem.29 In this alternative metabolic pathway, there is an
ctivation  of transcription factors (FoxO3) in cell nucleus,
ausing an increase in lysosomal and proteasomal proteolysis,
hich  will be responsible for mitochondrial and myoﬁbrillar
oss.29 In physiological terms, when the IGF1/insulin – P13k-
kt  signaling pathway is activated, FoxO3 is deactivated and
ytosol  is released.30
Lipodystrophy is classiﬁed on a clinical and subjective
asis.3,7,8 Accordingly, the assessment of anthropometric
easurements and body composition could be instruments
hat  help detecting clinical and metabolic changes. Although
he  average value of waist circumference did not show a
igniﬁcant  statistical difference (p = 0.051), a result that may
e  limited due to the sample size, this variable was higher
n  the group with lipodystrophy. Additionally, values of cor-
elation  coefﬁcient and linear regression showed that waist
ircumference is related to anthropometric indexes deter-
ining  lipodystrophy. Some studies suggest that metabolic
hanges also result from central adiposity, as well as insulin
esistance, which seems to be more  pronounced in the pres-
nce  of lipohypertrophy.31
A trunk to arm ratio may  be a good parameter for body
at  redistribution, which shows upper limb tapering and accu-
ulation  of fat in the abdominal area and dorsal hump.12 In
his  study, we  demonstrated the positive association of this
atio  with lipodystrophy. The higher the index obtained by the
atio,  the greater the amount of fat in the trunk and reduc-
ion  thereof in the upper limbs. This index is easy to apply,
btained through skinfolds, being feasible in clinical practice.
In  the study population, no changes were  veriﬁed in the
ercentage of fat in lower and upper limbs when compared
o  the groups with and without lipodystrophy, however the
atio  limb to trunk obtained through DXA showed a strong
orrelation with this clinical change. In another study carried
ut  with children using HAART compared to a control group,
hanges  in body composition obtained through DXA were also
7oted, even in the absence of clinical signs of lipodystrophy.
herefore, the clinical diagnosis of lipodystrophy seems to
e  underestimated. Vigano et al., demonstrated that 31/37
f  patients non-identiﬁed as lipodystrophic patients showed 0 1 3;1 7(1):1–6  5
changes  in body composition, such as fat reduction in lower
limbs  and increase in visceral adiposity through DXA. Only
8/37  of these patients were  provided with the same clinical
and  image  diagnosis of lipodystrophy.8
The results of this study show limitations as it is a cross
sectional study, which only considers variables at the moment
of  data collection, in addition to the limited sample regarding
population seen at this clinic. Thus, it would be ideal to have
a  cohort study to better assess the metabolic side effects com-
pared  to changes in body composition. On the other hand,
the  study shows a homogeneous sample as to age, pubertal
stage,  severity of the disease and use of antiretroviral drugs,
supporting the results obtained.
Assessment of body composition through DXA has the dis-
advantage  of requiring costly technology, therefore, the use of
anthropometric  measurements, obtained through skinfolds,
presents  a feasible and low-cost alternative.
The trunk to arm and limb to trunk ratios may  be used
as  indicators of preclinical lipodystrophy. No cutoffs were
established to such values yet, requiring subsequent studies;
however,  continuous monitoring of these ratios may  identify
changes  in body composition of these patients early.
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